GlassScriptPhysician profile
Andrew S Morgenstern
NPI 1598850208
$62,462.74
in general payments reported to CMS, 2019-2025
17 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $1,787 · 2021: $2,707 · 2022: $4,729 · 2023: $2,240 · 2024: $1,817 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,624 · Consulting Fee: $1,840 · Travel and Lodging: $1,312 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $3,623.50 |
| Consulting Fee | $1,840.00 |
| Travel and Lodging | $1,312.46 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $24,933.31 | 2019-2023 | Total30 |
| Tarsus Pharmaceuticals, INC. | $17,885.40 | 2024-2025 | Xdemvy |
| Oculus, INC. | $5,750.00 | 2021-2023 | Myopia Master |
| Sun Pharmaceutical Industries INC. | $4,956.49 | 2019-2023 | Cequa |
| Sight Sciences, INC. | $1,892.31 | 2020-2023 | Tearcare System |
| Glaukos Corporation | $1,852.92 | 2019-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Johnson & Johnson Surgical Vision, INC. | $1,840.36 | 2019 | |
| Abbvie INC. | $1,454.82 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $546.88 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Allergan, INC. | $522.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $235.17 | 2019 | |
| Carl Zeiss Meditec, INC. | $206.73 | 2019-2020 | |
| Oyster Point Pharma, INC. | $153.37 | 2022-2023 | Tyrvaya |
| Horizon Therapeutics Plc | $149.31 | 2022 | |
| Immunogen, INC. | $33.14 | 2023 | Elahere |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.19 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Morgenstern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.